We tested the plasma of 51 HIV-1-infected children (23 naïve and 28 ART treated) for neutralization against five primary isolates (PIs) generated from adult Indian HIV-1-infected patients. The plasma exhibited neutralization potential with significantly higher neutralizing antibody titers in ART-treated children than naïve children against three out of five PIs (p<0.0001). Further, in treated children, neutralizing antibody titers were higher in those children with suppressed viremia (<1000 RNA copies/mL) than non-suppressors against two of the three PIs. We report here for the first time the neutralization potential of the plasma of HIV-1-infected Indian children.
Get full access to this article
View all access options for this article.
References
1.
BinleyJ. Specificities of broadly neutralizing anti-HIV-1 sera. Curr Opin HIV AIDS, 2009; 4:364–372.
2.
BinleyJM, TrkolaA, KetasTet al.The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis, 2000; 182:945–949.
3.
BongertzV, OuverneyEP, FernandezSCet al.Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment. Mem Inst Oswaldo Cruz, 2007; 102:817–825.
4.
BrolidenK, SieversE, TovoPAet al.Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children. Clin Exp Immunol, 1993; 93:56–64.
5.
ChakrabortyR. HIV-1 infection in children: A clinical and immunologic overview. Curr HIV Res, 2005; 3:31–41.
6.
DeviNP, ShenbagavalliR, RameshK, RathinamSN, SwaminathanS. Rapid progression of HIV infection in infancy. Indian Pediatr, 2009; 46:53–56.
7.
DreyerK, KallasEG, PlanellesV, MontefioriD, McDermottMP, HasanMS, EvansTG. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses, 1999; 15:1563–1571.
8.
FalkensammerB, FreissmuthD, HubnerL, SpethC, DierichMP, StoiberH. Changes in HIV-specific antibody responses and neutralization titers in patients under ART. Front Biosci, 2007; 12:2148–2158.
9.
GeffinR, HuttoC, AndrewC, ScottGB. A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. Virology, 2003; 310:207–215.
10.
Global report: UNAIDS report on the global AIDS epidemic 2010. http://www.unaids.org/documents/20101123_GlobalReport_em.pdf. 2011 March 15.
11.
HumbertM, DietrichU. The role of neutralizing antibodies in HIV infection. AIDS Rev, 2006; 8:51–59.
12.
KimJH, MascolaJR, Ratto-KimSet al.Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res Hum Retroviruses, 2001; 17:1021–1034.
13.
MontefioriDC. Protocol for measuring neutralizing antibodies against HIV-1, SIV, SHIV using a luciferase reporter gene assay in TZM-BL cells. 2008. http://www.hiv.lanl.gov/content/nab-reference-strains/html/Protocol-Neutralizing-Antibody-Assay-for-HIV-1-in-TZM-bl-Cells-July-2008.pdf. 2011 January 15.
14.
MontefioriDC, AltfeldM, LeePKet al.Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1 infected individual. J Immunol, 2003; 170:3906–3914.
15.
MontefioriDC, HillTS, VoHT, WalkerBD, RosenbergES. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol, 2001; 75:10200–10207.
16.
MorrisL, BinleyJM, ClasBAet al.HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med, 1998; 188:233–245.
17.
MorrisMK, KatzensteinDA, IsraelskiD, ZolopaA, HendryRM, HansonCV. Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART)J Acquir Immune Defic Syndr, 2001; 28:405–415.
18.
NACO Annual Report 2009-10. http://www.nacoonline.org/upload/AR%202009-10/NACO_AR_English%20corrected.pdf. 2011 March 15.
19.
NACO guidelines for HIV care and treatment in infants and childrenNovember2006. http://www.whoindia.org/LinkFiles/HIV-AIDS_NACO_guidelines_on_ART_for_paediatric_HIV_AIDS.pdf. 2011 March 01.
20.
NandiA, LavineCL, WangPet al.NIAID Center for HIV/AIDS Vaccine Immunology: Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology, 2010; 396:339–348.
21.
NesheimSR, KapogiannisBG, SoeMMet al.Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986–2004. Pediatrics, 2007; 120:100–109.
22.
OrtizGM, NixonDF, TrkolaAet al.HIV-1 specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest, 1999; 104:R13–R18.
23.
PalumboPE, RaskinoC, FiscusSet al.Disease progression in HIV infected infants and children: Predictive value of HIV RNA and CD4 lymphocyte count. JAMA, 1998; 279:756–761.
24.
Robert-GuroffM, RoilidesE, MuldoonRet al.Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value. J Infect Dis, 1993; 167:538–546.
25.
ZhangH, HoffmanF, HeJet al.Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology, 2006; 3:73.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
